{
    "id": "5e639a8b1af46fc130000011",
    "question": "Is Li\u2013Fraumeni syndrome a rare, autosomal recessive, hereditary disorder that predisposes carriers to cancer development?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "B",
    "predict": "{\"step_by_step_thinking\": \"To answer this question, we need to analyze the characteristics of Li-Fraumeni syndrome. Li-Fraumeni syndrome is a genetic disorder that predisposes individuals to develop multiple types of cancer, including breast cancer, sarcomas, brain tumors, and others. According to the provided documents, Li-Fraumeni syndrome is caused by germline mutations in the TP53 gene. This suggests that Li-Fraumeni syndrome is an autosomal dominant disorder, not autosomal recessive. The fact that a single mutation in one allele is sufficient to predispose individuals to cancer development also supports this conclusion. Furthermore, Li-Fraumeni syndrome is characterized by a high penetrance, meaning that individuals with the mutation have a high risk of developing cancer. This is consistent with an autosomal dominant pattern of inheritance. Therefore, Li-Fraumeni syndrome is not a rare, autosomal recessive disorder. Instead, it is a rare, autosomal dominant hereditary disorder that predisposes carriers to cancer development.\", \"answer_choice\": \"B\"}",
    "snippets": [
        {
            "id": "Pathology_Robbins_1266",
            "title": "Pathology_Robbins",
            "content": "individuals to develop malignant tumors because only one additional hit is needed to inactivate the second, normal allele. Patients with the Li-Fraumeni syndrome have a 25-fold greater chance of developing a malignant tumor by 50 years of age compared with the general population. In contrast to tumors developing in patients who inherit a mutant RB allele, the spectrum of tumors that develop in patients with the Li-Fraumeni syndrome is much more varied; the most common types are sarcomas, breast cancer, leukemia, brain tumors, and carcinomas of the adrenal cortex. Compared with individuals diagnosed with sporadic tumors, patients with Li-Fraumeni syndrome develop tumors at a younger age and may develop multiple primary tumors."
        },
        {
            "id": "InternalMed_Harrison_6059",
            "title": "InternalMed_Harrison",
            "content": "cancer to the presence of modifier alleles. syndrome (BRCA1 and BRCA2 genes), Lynch\u2019s syndrome (mismatch repair genes), Li-Fraumeni syndrome (TP53 gene), Cowden syndrome (PTEN gene), hereditary retinoblastoma (RB1 gene), and others."
        },
        {
            "id": "Surgery_Schwartz_2361",
            "title": "Surgery_Schwartz",
            "content": "P, Tamminen A, Karvinen P, et al. p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition. Cancer Res. 2001;61:5718-5722. 52. DiCiommo D, Gallie BL, Bremner R. Retinoblastoma: the disease, gene and protein provide critical leads to understand cancer. Semin Cancer Biol. 2000;10:255-269. 53. Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer. 2001;1:157-162. 54. Li FP, Fraumeni JF, Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med. 1969;71:747-752. 55. Li FP, Fraumeni JF, Jr., Mulvihill JJ, et al. A cancer fam-ily syndrome in twenty-four kindreds. Cancer Res. 1988;48:5358-5362. 56. Birch JM, Hartley AL, Tricker KJ, et al. Prevalence and diver-sity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res. 1994;54:1298-1304. 57. Birch JM, Alston RD, McNally RJ, et al. Relative frequency and morphology of cancers in"
        },
        {
            "id": "Pathology_Robbins_1264",
            "title": "Pathology_Robbins",
            "content": "Confirming the importance of TP53 in controlling carcinogenesis, more than 70% of human cancers have a defect in this gene, and the remaining malignant neoplasms often have defects in genes upstream or downstream of TP53. Biallelic abnormalities of the TP53 gene are found in virtually every type of cancer, including carcinomas of the lung, colon, and breast\u2014the three leading causes of cancer deaths. In most cases, mutations affecting both TP53 alleles are acquired in somatic cells. In other tumors, such as certain sarcomas, the TP53 gene is intact but p53 function is lost because of amplification and over-expression of the MDM2 gene, which encodes a potent inhibitor of p53. Less commonly, patients inherit a mutant TP53 allele; the resulting disorder is called the Li-Fraumeni syndrome. As in the case with familial retinoblastoma, inheritance of one mutant TP53 allele predisposes affected http://ebooksmedicine.net"
        },
        {
            "id": "Surgery_Schwartz_2142",
            "title": "Surgery_Schwartz",
            "content": "and Li-Fraumeni Syndrome. Li-Fraumeni syndrome (LFS) was first defined on the basis of observed clustering of malignancies, including early-onset breast cancer, soft tissue sarcomas, brain tumors, adrenocortical tumors, and leukemia.54 Criteria for classic LFS in an individual (the proband) include: (a) a bone or soft tissue sarcoma when younger than 45 years, (b) a first-degree relative with cancer before age 45 years, and (c) another firstor second-degree relative with either a sar-coma diagnosed at any age or any cancer diagnosed before age 45 years.55 Approximately 70% of LFS families have been shown to have germline mutations in the tumor-suppressor gene p53.56 Breast carcinoma, soft tissue sarcoma, osteosarcoma, brain tumors, adrenocortical carcinoma, Wilms\u2019 tumor, and phyllodes tumor of the breast are strongly associated; pancre-atic cancer is moderately associated; and leukemia and neuro-blastoma are weakly associated with germline p53 mutations.57 Mutations of p53 have not"
        },
        {
            "id": "Surgery_Schwartz_3819",
            "title": "Surgery_Schwartz",
            "content": "seen), Li-Fraumeni syndrome (TP53 mutations, also associated with sarcomas, lymphomas, and adrenocortical tumors), hereditary diffuse gastric cancer syndrome (CDH1 mutations, associated with diffuse gastric cancer and lobular breast cancers), and syndromes of breast and melanoma. With the discovery of additional genes related to breast cancer susceptibility, panel testing is available for a number of genes in addition to BRCA1 and BRCA2. The inter-pretation of results is complex and is best done with a genetic counselor.EPIDEMIOLOGY AND NATURAL HISTORY OF BREAST CANCEREpidemiologyBreast cancer is the most common site-specific cancer in women and is the leading cause of death from cancer for women age 20 to 59 years. Based on Surveillance, Epidemiology, and End Results registries (SEER) data, 266,120 new cases were esti-mated in 2018 with 40,920 estimated deaths attributed to breast cancers.117 It accounts for 30% of all newly diagnosed cancers in women and is responsible for 14% of"
        },
        {
            "id": "InternalMed_Harrison_6058",
            "title": "InternalMed_Harrison",
            "content": "Although the Mendelian forms of cancer have taught us much addition, the decision to test should depend on whether effective inter-about the mechanisms of growth control, most forms of cancer do not ventions exist for the particular type of cancer to be tested. Despite follow simple patterns of inheritance. In many instances (e.g., lung these caveats, genetic cancer testing for some cancer syndromes cancer), a strong environmental contribution is at work. Even in such already appears to have greater benefits than risks. Companies offer circumstances, however, some individuals may be more genetically genetic testing for many of the cancer syndromes listed in Table 83-3, susceptible to developing cancer, given the appropriate exposure, due including FAP (APC gene), hereditary breast and ovarian cancer to the presence of modifier alleles. syndrome (BRCA1 and BRCA2 genes), Lynch\u2019s syndrome (mismatch repair genes), Li-Fraumeni syndrome (TP53 gene), Cowden syndrome (PTEN gene), hereditary"
        },
        {
            "id": "Surgery_Schwartz_3798",
            "title": "Surgery_Schwartz",
            "content": "as an autosomal dominant trait with high pen-etrance. Approximately 50% of children of carriers inherit the trait. In general, BRCA1-associated breast cancers are invasive ductal carcinomas, are poorly differentiated, are in the majority Brunicardi_Ch17_p0541-p0612.indd 55801/03/19 5:04 PM 559THE BREASTCHAPTER 17Table 17-7Incidence of sporadic, familial, and hereditary breast cancerSporadic breast cancer65%\u201375%Familial breast cancer20%\u201330%Hereditary breast cancer5%\u201310% BRCA1a45% BRCA235% p53a (Li-Fraumeni syndrome)1% STK11/LKB1a (Peutz-Jeghers syndrome)<1% PTENa (Cowden disease)<1% MSH2/MLH1a (Muir-Torre syndrome)<1% ATMa (Ataxia-telangiectasia)<1% Unknown20%aAffected gene.Data from Martin AM, Weber BL: Genetic and hormonal risk factors in breast cancer, J Natl Cancer Inst. 2000 Jul 19;92(14):1126-1135.hormone receptor negative, and have a triple receptor negative (immunohistochemical profile: ER-negative, PR-negative, and HER2-negative) or basal phenotype (based on gene"
        },
        {
            "id": "InternalMed_Harrison_7664",
            "title": "InternalMed_Harrison",
            "content": "Li-Fraumeni syndrome is a familial cancer syndrome in which affected individuals have germline abnormalities of the tumor- suppressor gene p53 and an increased incidence of soft tissue sarcomas and other malignancies, including breast cancer, osteosarcoma, brain tumor, leukemia, and adrenal carcinoma (Chap. 101e). Neurofibromatosis 1 (NF-1, peripheral form, von Recklinghausen\u2019s disease) is characterized by multiple neurofibromas and caf\u00e9-au-lait spots. Neurofibromas occasionally undergo malignant degeneration to become malignant peripheral nerve sheath tumors. The gene for NF-1 is located in the pericentromeric region of chromosome 17 and encodes neurofibromin, a tumor-suppressor protein with guanosine 5\u2032-triphosphate (GTP)ase-activating activity that inhibits Ras function 119e-1 (Chap. 118). Germline mutation of the Rb-1 locus (chromosome 13q14) in patients with inherited retinoblastoma is associated with the development of osteosarcoma in those who survive the retinoblastoma and of"
        },
        {
            "id": "InternalMed_Harrison_6683",
            "title": "InternalMed_Harrison",
            "content": "First-degree relatives of lung cancer probands have a twoto threefold excess risk of lung cancer and other cancers, many of which are not smoking-related. These data suggest that specific genes and/or genetic variants may contribute to susceptibility to lung cancer. However, very few such genes have yet been identified. Individuals with inherited mutations in RB (patients with retinoblastoma living to adulthood) and p53 (Li-Fraumeni syndrome) genes may develop lung cancer. Common gene variants involved in lung cancer have been recently identified through large, collaborative, genome-wide association studies. These studies identified three separate loci that are associated with lung cancer (5p15, 6p21, and 15q25) and include genes that regulate acetylcholine nicotinic receptors and telomerase production. A rare germline mutation (T790M) involving the epidermal growth factor receptor (EGFR) maybe be linked to lung cancer susceptibility in never smokers. Likewise, a susceptibility locus"
        },
        {
            "id": "InternalMed_Harrison_6049",
            "title": "InternalMed_Harrison",
            "content": "Roughly 100 syndromes of familial cancer have been reported, although many are rare. The majority are inherited as autosomal dominant traits, although some of those associated with DNA repair abnormalities (xeroderma pigmentosum, Fanconi\u2019s anemia, ataxia telangiectasia) are autosomal recessive. Table 101e-3 shows a number of cancer predisposition syndromes and the responsible genes. The current paradigm states that the genes mutated in familial syndromes can also be targets for somatic mutations in sporadic (noninherited) tumors. The study of cancer syndromes has thus provided invaluable insights into the mechanisms of progression for many tumor types. This section examines the case of inherited colon cancer in detail, but A1 Loss of normal chr 13 A3 B1 B3 Markers:"
        },
        {
            "id": "Gynecology_Novak_3322",
            "title": "Gynecology_Novak",
            "content": "The patient should be questioned about the following risk factors for breast cancer (see Chapter 40 for more details): Increasing age (approximately 50% of breast cancers occur after age 65) Age of menarche less than 12 years Nulliparity or first pregnancy at greater than 30 years of age Late menopause (older than 55 years of age) Family history of breast cancer (especially premenopausal or bilateral disease) Number of first-degree relatives with breast cancer and their ages when diagnosed Family history of male breast cancer Inherited conditions associated with a high risk for breast cancer, including BRCA1 and BRCA2 genes, Li-Fraumeni syndrome, Cowden\u2019s disease, ataxia telangiectasia syndrome, and Peutz-Jeghers syndrome Other malignancies (ovary, colon, and prostate) Pathology of previous breast biopsy showing atypia or lobular or ductal carcinoma Hormone therapy Alcohol consumption Postmenopausal weight gain Personal history of breast cancer"
        },
        {
            "id": "InternalMed_Harrison_6100",
            "title": "InternalMed_Harrison",
            "content": "exposure leads to mutation of arginine to serine at codon 249 and leads to hepatocellular carcinoma. In rare instances, p53 mutations are in the germline (Li-Fraumeni syndrome) and produce a familial cancer syndrome."
        },
        {
            "id": "Surgery_Schwartz_2141",
            "title": "Surgery_Schwartz",
            "content": "that a single mutation is not sufficient for tumorigenesis. Alfred Knudson hypothesized that hereditary retinoblastoma involves two mutations, of which one is germ-line and one somatic, whereas nonhereditary retinoblastoma is due to two somatic mutations (Fig. 10-12).53 Thus, both heredi-tary and nonhereditary forms of retinoblastoma involve the same number of mutations, a hypothesis known as Knudson\u2019s \u201ctwo-hit\u201d hypothesis. A \u201chit\u201d may be a point mutation, a chro-mosomal deletion referred to as allelic loss, or a loss of hetero-zygosity, or silencing of an existing gene. Approximately 40% of retinoblastomas are hereditary and due to germline mutations in the RB1 gene. Children with hereditary RB are also at risk for developing a midline intracranial tumor, most commonly pineoblastoma.p53 and Li-Fraumeni Syndrome. Li-Fraumeni syndrome (LFS) was first defined on the basis of observed clustering of malignancies, including early-onset breast cancer, soft tissue sarcomas, brain tumors,"
        },
        {
            "id": "InternalMed_Harrison_4998",
            "title": "InternalMed_Harrison",
            "content": "Adult-onset hereditary diseases follow multiple patterns of inheritance. Some are autosomal dominant conditions. These include many common cancer susceptibility syndromes such as hereditary breast and ovarian cancer (due to germline BRCA1 and BRCA2 mutations) and Lynch syndrome (caused by germline mutations in the mismatch repair genes MLH1, MSH2, MSH6, and PMS2). In both of these examples, inherited mutations are associated with a high penetrance (lifetime risk) of cancer, although risk is not 100%. In other conditions, although there is autosomal dominant transmission, there is lower penetrance, thereby making the disorders more difficult to recognize. For example, germline mutations in CHEK2 increase the risk of breast cancer, but with a moderate lifetime risk in the range of 20\u201340%, as opposed to 50\u201370% for mutations in BRCA1 or BRCA2. Other adult-onset hereditary diseases are transmitted in an autosomal recessive fashion where two mutant alleles are necessary to cause disease."
        },
        {
            "id": "Surgery_Schwartz_3818",
            "title": "Surgery_Schwartz",
            "content": "CI, 25\u201344) for those with no family history of breast cancer to 58% (95% CI, 50\u201366) for those with two or more first-degree relatives with breast cancer at 50 years of age. The risk of breast cancer for female PALB2 mutation carriers, depending on the age, was about five to nine times as high compared with the gen-eral population. While screening with mammogram along with MRI has been suggested for PALB2 mutation carriers starting at age 30 with consideration of risk-reducing mastectomy, there is currently insufficient evidence regarding the risk of ovarian cancer and its management.Other hereditary syndromes associated with an increased risk of breast cancer include Cowden disease (PTEN mutations, in which cancers of the thyroid, GI tract, and benign skin and subcutaneous nodules are also seen), Li-Fraumeni syndrome (TP53 mutations, also associated with sarcomas, lymphomas, and adrenocortical tumors), hereditary diffuse gastric cancer syndrome (CDH1 mutations, associated with diffuse"
        },
        {
            "id": "InternalMed_Harrison_6832",
            "title": "InternalMed_Harrison",
            "content": "Human breast cancer is a clonal disease; a single transformed cell\u2014the product of a series of somatic (acquired) or germline mutations\u2014is eventually able to express full malignant potential. Thus, breast cancer may exist for a long period as either a noninvasive disease or an invasive but nonmetastatic disease. These facts have significant clinical ramifications. Not more than 10% of human breast cancers can be linked directly to germline mutations. Several genes have been implicated in familial cases. The Li-Fraumeni syndrome is characterized by inherited mutations in the p53 tumor-suppressor gene, which lead to an increased incidence of breast cancer, osteogenic sarcomas, and other malignancies. Inherited mutations in PTEN have also been reported in breast cancer."
        },
        {
            "id": "InternalMed_Harrison_27014",
            "title": "InternalMed_Harrison",
            "content": "Adrenocortical carcinoma (ACC) is a rare malignancy with an annual incidence of 1\u20132 per million population. ACC is generally considered a highly malignant tumor; however, it presents with broad interindividual variability with regard to biologic characteristics and clinical behavior. Somatic mutations in the tumor-suppressor gene TP53 are found in 25% of apparently sporadic ACC. Germline TP53 mutations are the cause of the Li-Fraumeni syndrome associated with multiple solid organ cancers including ACC and are found in 25% of pediatric Disorders of the Adrenal Cortex 24-h urine for free cortisol excretion, plasma ACTH, midnight plasma (or salivary) cortisol, dexamethasone 1 mg overnight test (perform at least two out of four tests) If tumor >2 cm: Serum 17-hydroxyprogesterone and DHEAS imaging suggestive of malignancy: \u2022 Size >4 cm Negative and imaging not suggestive of malignancy: Neg. Pos. Neg. Pos."
        },
        {
            "id": "InternalMed_Harrison_6861",
            "title": "InternalMed_Harrison",
            "content": "combined with newer diagnostic techniques (MRI, magnetic resonance spectroscopy, positron emission tomography, etc.) may make it possible to identify breast cancers even more reliably and earlier. Screening by any technique other than mammography is not indicated. However, the ACS suggests that younger women who are BRCA1 or BRCA2 carriers or untested first-degree relatives of women with cancer; women with a history of radiation therapy to the chest between ages 10 and 30 years; women with a lifetime risk of breast cancer of at least 20%; and women with a history of Li-Fraumeni, Cowden, or Bannayan-Riley-Ruvalcaba syndromes may benefit from MRI screening, where the higher sensitivity may outweigh the loss of specificity."
        },
        {
            "id": "Surgery_Schwartz_2362",
            "title": "Surgery_Schwartz",
            "content": "of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res. 1994;54:1298-1304. 57. Birch JM, Alston RD, McNally RJ, et al. Relative frequency and morphology of cancers in carriers of germline TP53 muta-tions. Oncogene. 2001;20:4621-4628. 58. Birch JM, Blair V, Kelsey AM, et al. Cancer phenotype cor-relates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene. 1998;17:1061-1068. 59. Loman N, Johannsson O, Kristoffersson U, Olsson H, Borg A. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. J Natl Cancer Inst. 2001;93:1215-1223. 60. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet. 1994;343:692-695. 61. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer"
        },
        {
            "id": "Surgery_Schwartz_2196",
            "title": "Surgery_Schwartz",
            "content": "diagnosis may be preferable in a patient at high risk for breast cancer.98Cancer risk assessment starts with taking a complete his-tory that includes history of environmental exposures to potential carcinogens and a detailed family history. Risk assessment for breast cancer, for example, includes obtaining a family history to determine whether another member of the family is known to carry a breast cancer susceptibility gene; whether there is famil-ial clustering of breast cancer, ovarian cancer, thyroid cancer, sarcoma, adrenocortical carcinoma, endometrial cancer, brain tumors, dermatologic manifestations, leukemia, or lymphoma; and whether the patient is from a population at increased risk, such as individuals of Ashkenazi Jewish descent. Patients who have a family history suggestive of a cancer susceptibility syn-drome such as hereditary breast-ovarian syndrome, Li-Fraumeni Syndrome, or Cowden\u2019s Disease would benefit from genetic counseling and possibly genetic testing.There are"
        },
        {
            "id": "Pathology_Robbins_4885",
            "title": "Pathology_Robbins",
            "content": "Most sarcomas are sporadic and have no known predisposing cause. A small minority of soft tissue neoplasms are associated with germline mutations in tumor suppressor genes (neurofibromatosis 1, Gardner syndrome, Li-Fraumeni syndrome, Osler-Weber Rendu syndrome). A few tumors can be linked to known environmental exposures such as radiation, burns, or toxins. Unlike tumors such as colorectal carcinomas that usually arise from recognized precursor lesions, the origin of sarcomas is unknown. The best guess is that the tumors arise from pluripotent mesenchymal stem cells, which acquire somatic \u201cdriver\u201d mutations. Despite heterogeneous mechanisms of tumorigenesis among sarcomas, some generalizations can be made based on their genomic complexity:"
        },
        {
            "id": "Surgery_Schwartz_2197",
            "title": "Surgery_Schwartz",
            "content": "of a cancer susceptibility syn-drome such as hereditary breast-ovarian syndrome, Li-Fraumeni Syndrome, or Cowden\u2019s Disease would benefit from genetic counseling and possibly genetic testing.There are several models that can estimate risk based on complex family histories and assist clinicians in estimat-ing breast cancer risk or the likelihood that a BRCA mutation is present, including the Claus model, Tyrer-Cuzick model, BRCAPRO model, and the Breast and Ovarian Analysis of Dis-ease Incidence and Carrier Estimation Algorithm (BOADICEA) model.99-102 Patients who do have a strong hereditary component of risk can be evaluated on the basis of their age, race, per-sonal history, and exposures. One of the most commonly used models for risk assessment in breast cancer is the Gail model.103 Gail and colleagues analyzed the data from 2852 breast cancer cases and 3146 controls from the Breast Cancer Detection and Demonstration Project, a mammography screening project conducted in the 1970s,"
        },
        {
            "id": "Cell_Biology_Alberts_5627",
            "title": "Cell_Biology_Alberts",
            "content": "A Few Key Genetic Lesions Are Common to a Large Fraction of Colorectal Cancers What are the mutations that accumulate with time to produce this chain of events? Of those genes so far discovered to be involved in colorectal cancer, three stand out as most frequently mutated: the proto-oncogene K-Ras (a member of the Ras gene family), in about 40% of cases; p53, in about 60% of cases; and the tumor suppressor gene Apc (discussed below), in more than 80% of cases. Others are involved in smaller numbers of colon cancers, and some of these are listed in Table 20\u20131. The role of Apc first came to light through study of certain families showing a rare type of hereditary predisposition to colorectal cancer, called familial"
        },
        {
            "id": "InternalMed_Harrison_6099",
            "title": "InternalMed_Harrison",
            "content": "A second method of activating p53 involves the induction of p14ARF by hyperproliferative signals from oncogenes. p14ARF competes with p53 for binding to mdm2, allowing p53 to escape the effects of mdm2 and accumulate in the cell. Then p53 stops cell cycle progression by activating CDK inhibitors such as p21 and/or initiating the apoptosis pathway. Not surprisingly given its critical role in controlling cell cycle progression, mutations in the gene for p53 on chromosome 17p are found in more than 50% of human cancers. Most commonly these mutations are acquired in the malignant tissue in one allele and the second allele is deleted, leaving the cell unprotected from DNA-damaging agents or oncogenes. Some environmental exposures produce signature mutations in p53; for example, aflatoxin exposure leads to mutation of arginine to serine at codon 249 and leads to hepatocellular carcinoma. In rare instances, p53 mutations are in the germline (Li-Fraumeni syndrome) and produce a familial"
        },
        {
            "id": "InternalMed_Harrison_5020",
            "title": "InternalMed_Harrison",
            "content": "Testing strategies are evolving as a result of these new genetic testing platforms. As the cost of multiple gene panels and WES continue to fall, and as interpretation of such test results improve, there may be a shift from sequential single-gene (or a few genes) testing to multigene testing. For example, presently, a 30-year-old woman with breast cancer but no family history of cancer and no syndromic features would undergo BRCA1/2 testing. If negative, she would subsequently be offered TP53 testing. Notably, a reasonable number of individuals offered TP53 testing for Li-Fraumeni syndrome decline because mutations are associated with extremely high cancer risks (including childhood cancers) in multiple organs and there are no proven interventions to mitigate risk. Without features consistent with Cowden syndrome, the woman would not be routinely offered PTEN testing or testing for CHEK2, ATM, BRIP, BARD, NBN, and PALB2. However, it is now possible to synchronously analyze all of the"
        },
        {
            "id": "InternalMed_Harrison_7943",
            "title": "InternalMed_Harrison",
            "content": "risk of breast cancer in the opposite breast. Patients with Hodgkin\u2019s lymphoma are at risk for nonHodgkin\u2019s lymphomas. Genetic cancer syndromes (e.g., multiple endocrine neoplasia or Li-Fraumeni, Lynch\u2019s, Cowden\u2019s, and Gardner\u2019s syndromes) are examples of genetically based second malignancies of specific types. Cancer treatment itself does not appear to be responsible for the risk of these secondary malignancies. Deficient DNA repair can greatly increase the risk of cancers from DNA-damaging agents, as in ataxia-telangiectasia. Importantly, the risk of treatment-related second malignancies is at least additive and often synergistic with combined chemotherapy and radiation therapy, and hence for such combined-therapy treatment approaches, it is important to establish the necessity of each in the treatment program. All of these patients require special surveillance or, in some cases, prophylactic surgery as part of appropriate treatment and follow-up."
        },
        {
            "id": "Pediatrics_Nelson_3391",
            "title": "Pediatrics_Nelson",
            "content": "The cause is unknown for most children diagnosed with sarcoma, although a few observations have been made regarding risks. Individuals with Li-Fraumeni syndrome (associated with a germline p53 mutation) and neurofibromatosis (associated with NF1 mutations) have an increased risk of softtissue sarcomas. There is a 500-fold increased risk for osteosarcoma for individuals with hereditary retinoblastoma. Prior treatment for childhood cancer with radiation therapy or chemotherapy, specifically alkylating agents, or both, increases the risk for osteosarcoma as a second malignancy."
        },
        {
            "id": "InternalMed_Harrison_5009",
            "title": "InternalMed_Harrison",
            "content": "Although many inherited disorders will be suggested by the clustering of relatives with the same or related conditions, it is important to note that disease penetrance is incomplete for most genetic disorders. As a result, the pedigree obtained in such families may not exhibit a clear Mendelian inheritance pattern, because not all family members carrying the disease-associated alleles will manifest clinical evidence of the condition. Furthermore, genes associated with some of these disorders often exhibit variable disease expression. For example, the breast cancer\u2013associated gene BRCA2 can predispose to several different malignancies in the same family, including cancers of the breast, ovary, pancreas, skin, and prostate. For common diseases such as breast cancer, some family members without the susceptibility allele (or genotype) may develop breast cancer (or phenotype) sporadically. Such phenocopies represent another confounding variable in the pedigree analysis."
        },
        {
            "id": "InternalMed_Harrison_7942",
            "title": "InternalMed_Harrison",
            "content": "Second malignancies in patients cured of cancer are a major cause of death, and treated cancer patients must be monitored for their occurrence. The induction of second malignancies is governed by the complex interplay of a number of factors including age, gender, environmental exposures, genetic susceptibility, and cancer treatment itself. In a number of settings, the events leading to the primary cancer themselves increase the risk of second malignancies. Patients with lung cancer are at increased risk of esophageal and head and neck cancers, and vice versa, due to shared risk factors including alcohol and tobacco abuse. Indeed, the risk of developing a second primary head and neck, esophageal, or lung cancer is also increased in these patients. Patients with breast cancer are at increased risk of breast cancer in the opposite breast. Patients with Hodgkin\u2019s lymphoma are at risk for nonHodgkin\u2019s lymphomas. Genetic cancer syndromes (e.g., multiple endocrine neoplasia or Li-Fraumeni,"
        },
        {
            "id": "InternalMed_Harrison_5001",
            "title": "InternalMed_Harrison",
            "content": "Many diseases have multiple patterns of inheritance, adding to the complexity of evaluating patients and families for these conditions. For example, colon cancer can be associated with a single germline mutation in a mismatch repair gene (Lynch syndrome, autosomal dominant), biallelic mutations in MYH (autosomal recessive), or multiple SNPs (polygenic). Many more individuals will have SNP risk alleles than germline mutations in high-penetrance genes, but cumulative lifetime risk of colon cancer related to the former is modest, whereas the risk related to the latter is significant. Personal and family histories provide important insights into the possible mode of inheritance."
        },
        {
            "id": "InternalMed_Harrison_4999",
            "title": "InternalMed_Harrison",
            "content": "as opposed to 50\u201370% for mutations in BRCA1 or BRCA2. Other adult-onset hereditary diseases are transmitted in an autosomal recessive fashion where two mutant alleles are necessary to cause disease. Examples include hemochromatosis and MYH-associated colon cancer. There are more pediatric-onset autosomal recessive disorders, such as lysosomal storage diseases and cystic fibrosis."
        }
    ],
    "scores": [
        0.038494608209627475,
        0.036386465029710276,
        0.03604478343857743,
        0.034912570616809274,
        0.03462221661647774,
        0.03410373693392561,
        0.03358804591656988,
        0.03314448701507319,
        0.03263934729474832,
        0.03199925818674619,
        0.03126210915299125,
        0.02820588455067995,
        0.02736113313249828,
        0.026967997123336928,
        0.02511790011790012,
        0.025093370681605977,
        0.025068214988260677,
        0.024791409258187937,
        0.024788089399187647,
        0.024760424760424758,
        0.024173553719008263,
        0.024134248665141113,
        0.024065045543918785,
        0.0229470103570823,
        0.02290797058238919,
        0.022740213994385295,
        0.02245625216353231,
        0.0217480588289029,
        0.021354700854700856,
        0.021212684548885172,
        0.020396117790171378,
        0.020235048346486366
    ]
}